Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA reports news on its AI-driven precision medicine software business and the adoption of the SOPHiA DDM Platform by hospitals, laboratories, and biopharma institutions. Company updates commonly cover financial results, analysis volumes, customer additions, U.S. market expansion, and applications that analyze genomic and multimodal data for cancer and rare disorders.
Recurring developments include health-system collaborations, next-generation sequencing workflows for blood cancers and solid tumors, Liquid Biopsy and Enhanced Exomes applications, and management commentary on platform demand, gross margin, operating leverage, and biopharma activity.
SOPHiA GENETICS (Nasdaq: SOPH) has successfully closed its initial public offering, selling 13,000,000 ordinary shares at $18 each, generating gross proceeds of $234 million. Following this, the company also completed a private placement, issuing 1,111,111 ordinary shares to GE Healthcare for $20 million. The new shares began trading on the Nasdaq on July 23, 2021. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse were joint book-running managers for the IPO.
SOPHiA GENETICS has announced the pricing of its initial public offering (IPO) of 13,000,000 ordinary shares at $18 each, aiming to raise around $234 million in gross proceeds. The IPO is set to trade on the Nasdaq under the symbol 'SOPH' starting July 23, 2021, with the closing expected on July 27, 2021. Additionally, underwriters have a 30-day option to purchase up to 1,950,000 more shares. The company specializes in data-driven medicine through its SOPHiA DDM™ Platform, which serves over 780 institutions worldwide.